Keyword: Phibro Animal Health
Shares of Phibro Animal Health have fallen more than 25% since the beginning of the year, as the New Jersey company has come under pressure from the changing regulatory environment for antibiotics used in food production. Those pressures were evident in Phibro’s fourth-quarter and fiscal 2016 results.
Phibro Animal Health is disputing the FDA's plans to withdraw its approval of the company’s pig antibiotic, Mecadox (carbadox). It's fighting back with several new studies designed to prove the drug is safe.
Phibro Animal Health has suffered after the FDA said that it would crack down on the company’s antibiotic for pigs. Phibro’s regulatory woes took their toll on Q3 earnings, with sales that rang in lower than last year’s numbers.
Phibro Animal Health is responding to the FDA’s threatened withdrawal of its pig antibiotic Mecadox by emphasizing that the product has undergone extensive safety reviews. But questions have been raised worldwide about whether the drug leaves residues in pork that poses a cancer risk to people.
Investors have been cautious about medicated feed maker Phibro Animal Health, as concerns about food producers moving away from antibiotics have been on the rise of late. But if the company's fiscal fourth-quarter and full-year results are any indication, the company seems to be weathering the market shifts.
TEANECK, N.J., May 11, 2015 (GLOBE NEWSWIRE) -- Phibro Animal Health Corporation (Nasdaq:PAHC) today announced its financial results for its third quarter ended March 31, 2015. Highlights for the...
TEANECK, N.J., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Phibro Animal Health Corporation (Nasdaq:PAHC) today announced its financial results for its second quarter ended December 31, 2014. Highlights for...